Strata Critical Medical, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRTA research report →
Range $7.25 – $7.25
Price Chart
About the company
Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical assistance. A significant part of their operations involves the movement of human organs for transplant, utilizing both aerial and ground transportation methods.
- CEO
- Melissa Tomkiel
- IPO
- 2019
- Employees
- 327
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on SRTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $407.30M
- P/E
- -18.03
- Fwd P/E
- 58.84
- PEG
- 0.11
- P/S
- 1.67
- P/B
- 1.67
- EV/EBITDA
- -48.40
- Div Yield
- 0.00%
- Gross Margin
- 20.59%
- Op Margin
- -6.63%
- Net Margin
- -8.84%
- ROE
- -8.86%
- ROIC
- -6.54%
Latest fiscal year · YoY change
- Revenue
- $197.14M-20.7%
- Gross Profit
- $41.13M-30.2%
- Op Income
- $-22,353,000
- Net Income
- $41.35M+251.4%
- EPS
- $0.50+242.9%
- OCF Growth
- -1841.8%
- FCF Growth
- -68.7%
- 52W High
- $6.50
- 52W Low
- $3.95
- 50D MA
- $5.01
- 200D MA
- $5.10
- Beta
- 2.56
- RSI (14)
- 38
- Avg Volume
- 981.58K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Strata Critical Medical delivered a strong Q3 with revenue, EBITDA, and free cash flow all improving, while management raised confidence in its integrated transplant model, M&A capacity, and shareholder returns.· November 3, 2026
- Q3 revenue rose 50.3% year over year to $74.1 million, with total gross margin expanding to 22.7%.
- Adjusted EBITDA increased to $9.6 million from $4.2 million a year ago, and free cash flow hit a record $8.6 million.
- Clinical revenue grew 20.3% sequentially, reflecting market share gains and the full-quarter impact of recent acquisitions.
- Logistics revenue was softer on seasonality and shorter trip distances, but logistics gross margin rebounded to 20.8%, above management’s 2027 target.
- The company ended with $41.6 million in cash and short-term investments, announced a $20 million share repurchase authorization, and said it is still pursuing M&A at mid-single-digit EBITDA multiples.
Total revenue increased 50.3% to $74.1 million in Q3 2026 versus $49.3 million in the prior year period. Total gross profit rose 57.9% to $16.8 million, and total gross margin improved 110 basis points to 22.7% from 21.6%. Adjusted EBITDA was $9.6 million versus $4.2 million in Q3 2025 and $7.9 million in Q2 2026, with adjusted EBITDA margin at 13% versus 8.5% and 10.9%, respectively. Free cash flow was $8.6 million, cash flow from operations was $9.5 million, and capital expenditures were $0.8 million. The company ended Q3 with $41.6 million in cash and short-term investments and received net proceeds of $15.3 million from the first passenger business earn-out; it also cited an additional $27.5 million of potential earnout consideration and holdbacks release in Q1 2027. Management reiterated full-year 2026 guidance for revenue of $285 million to $295 million, adjusted EBITDA of $33 million to $35 million, and free cash flow before aircraft and engine acquisitions of $15 million to $22 million. It also said Q4 should show low single-digit sequential revenue growth at the midpoint, with logistics expected to be about flat quarter over quarter and gross margin about flat sequentially.
Will Heyburn framed the quarter as evidence that Strata’s integrated transplant strategy is working, citing market share gains, better margin mix, and strong cash generation. He emphasized that the company is ahead of its medium-term goals, believes it is on track for high-teens organic adjusted EBITDA growth and 30% plus total adjusted EBITDA growth in 2027, and sees room to accelerate acquisitions. His tone was confident and capital-allocation focused, highlighted by the new $20 million buyback authorization and comments that the company can both buy businesses and return cash to shareholders.
Matt Schneider mainly handled the introductory remarks and corporate housekeeping, while Will Heyburn covered the detailed financials. The company reported sequential clinical revenue growth of 20.3%, clinical gross margin of 25.6% versus 26.1% in Q2, logistics gross margin of 20.8% versus 18.4% in Q2, and adjusted SG&A of $8.9 million, up $1.5 million year over year but down $0.2 million sequentially. Management also said stock-based compensation was elevated at $5 million in Q3 and expects it to fall 20% to 30% sequentially in Q4, with a lower run rate persisting into 2027 alongside continued SG&A leverage. Cash generation was a key theme: $9.5 million of operating cash flow, $8.6 million of free cash flow, and no material near-term capital need for additional aircraft purchases.
Analysts focused on policy changes, flight distances, the logistics competitive environment, and the new cardiothoracic locum tenens business. Management said it has minimal exposure to any single OPO and only about 3% exposure to Tier 3 based on last year’s data, while arguing the new OPO rule and broader regulatory changes should ultimately support more successful organ placement. On lung distances, management said the Q3 move looked more like a tweak to allocation weighting than a structural reversal, and that heart and liver continuous distribution could eventually lift distances and volumes. On logistics competition, management said conditions are steady, any leakage is one-off, and that the share of flights carrying the OCS device should decline as customers shift toward NRP and other preservation methods.
The call showed a business with strong operating leverage: revenue, gross profit, adjusted EBITDA, and free cash flow all improved, while margins held up despite seasonality and shorter trip distances. Management also believes the integrated clinical platform is still early in its run, with customer adoption, NRP penetration, and new service lines like cardiothoracic locum tenens expanding the addressable market.
Logistics remains exposed to shorter industry trip distances, seasonal volume weakness, and some customer mix changes, and management said Q4 has not yet seen the normal seasonal pickup in transplant activity. Clinical growth is still being supported by acquisitions and investments in staff and training, and management acknowledged that stock-based compensation was elevated at $5 million in Q3, with margins expected to stay roughly flat in Q4 before improving later.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 52.0%
- Shares Outstanding
- 89.32M
- Float Shares
- 46.46M
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 112 ETFs
Biggest fund positions in SRTA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 5, 26 | LAUCK ANDREW | buy | 2,000 |
| Oct 28, 26 | Wunsch Scott M | other | 1,416 |
| Oct 28, 26 | Wunsch Scott M | other | 57,173 |
| Oct 28, 26 | Wunsch Scott M | other | 44,996 |
| Oct 28, 26 | Wunsch Scott M | other | 57,173 |
| Jul 30, 26 | Wunsch Scott M | other | 2,658 |
| Jul 30, 26 | Wunsch Scott M | other | 9,787 |
| Sep 24, 26 | Tomkiel Melissa M. | other | 177,858 |
| Sep 24, 26 | Tomkiel Melissa M. | other | 90,797 |
| Sep 24, 26 | Heyburn William A. | other | 177,858 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SRTA coverage
Recent articles, reports, and earnings notes.
No research on SRTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SRTA report →Strata Critical Medical, Inc. (SRTA) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 10
Strata Critical Medical Q3 Earnings Call Highlights
defenseworld.net · Nov 5
Strata Critical Medical to Present at the UBS Global Healthcare Conference
globenewswire.com · Nov 3
Strata Critical Medical, Inc. (SRTA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
Strata Critical Medical Q3 Earnings Call Highlights
marketbeat.com · Nov 3
Strata Critical Medical Announces Third Quarter 2026 Results
globenewswire.com · Nov 3
Strata Critical Medical Schedules Third Quarter 2026 Earnings Conference Call
globenewswire.com · Oct 23
Strata Critical to Present at the 2026 Jefferies Healthcare Services and Technology Conference
globenewswire.com · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.